Dynasil Corporation of America Reports First Quarter Fiscal 2014 Financial Results

Company Sells Instruments Businesses and Returns to Profitability

Feb 12, 2014, 07:50 ET from Dynasil Corporation of America

WATERTOWN, Mass., Feb. 12, 2014 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced financial results for the fiscal 2014 first quarter ended December 31, 2013. 

Dynasil reported net income for the quarter of $1,458,000 or $0.10 per share, compared with a net loss of ($379,000), or ($0.03) per share, for the quarter ended December 31, 2012.  Net income for the quarter includes a gain of $1,187,000 associated with the sale of the Company's lead paint and medical products businesses. 

"I am very happy to report that this quarter's results mark a return to profitability, a substantial reduction in our senior debt and compliance with our bank covenant ratios and the Nasdaq listing requirements," said Dynasil Chairman and Interim CEO Peter Sulick.  "In addition, we successfully completed the sale of our LPX and Navigator product lines and the contribution of our tissue sealant technology to Xcede Technologies, Inc., a joint venture with Mayo Clinic.  We expect Xcede to independently raise future funding for the continuing development of this promising technology."

Net revenue for the first quarter of fiscal 2014 increased slightly to $10.7 million, compared with $10.6 million for the first quarter of fiscal 2013.  Revenue increased approximately $900,000 or 19% in the Contract Research segment in the quarter while the Instruments segment declined approximately $500,000 or 40% primarily as a result of the sale of the lead paint and medical products businesses.  Gross profit for the first quarter of 2014 declined slightly to $4.5 million from $4.6 million for the same period in 2013.  Gross margins decreased to 41.5% in the quarter compared to 43.8% for the first quarter of fiscal 2013. 

Operating expenses for the three months ended December 31, 2013 were $4.0 million, a decrease of $883,000 compared to the same period in 2013.  The decrease was primarily a result of reduced product development costs associated with the lead paint and medical products businesses which were sold during the quarter ended December 31, 2013.

The Company is in compliance with the debt covenants ratios included in its senior loan agreement for the three months ended December 31, 2013, but has not yet paid interest due to its subordinated lender or obtained waivers from both its lenders for its covenant violations for prior periods, and thus remains in default with both of its lenders.  The Company has made all principal and interest payments due to its senior lender through February 12, 2014, the date of this earnings release, and has accrued but has not paid approximately $400,000 due to its subordinated lender since February, 2013.   Management has initiated discussions with its lenders in order to address the default situation.  However, the Company cannot predict when or whether a resolution of this situation will be achieved.

Quarterly Business Highlights

The Company successfully completed three transactions within the first quarter of fiscal 2014 that were important steps in significantly reducing its debt with Santander Bank and returning the Company to profitability.  On October 1, 2013, Dynasil Biomedical formed Xcede, a joint venture with the Mayo Clinic, to spin out and separately fund the development of its tissue sealant technology.  Xcede has initiated financing efforts and has received funding from outside investors including certain directors of the Company.  On November 7, 2013, the Company sold its lead paint detector business to Protec Instrument Corporation, which is a wholly owned subsidiary of Laboratoires Protec S.A., a French corporation and former European distributor of the lead paint detector products; and on December 23, 2013, Dynasil sold its Gamma Medical Probe business to Dilon Technologies, Inc.   Approximately $3.9 million of the proceeds from the sales were used to reduce the Company's bank debt.

"Now that we have been successful in reducing our debt and returning to profitability, the Company can continue to pursue various commercialization opportunities arising from technologies developed within our Contract Research segment," stated Mr. Sulick.  "We are continuing our efforts to further improve the size and quality of our CLYC crystals and have other exciting new technologies in development."  

The Company has no conference calls scheduled at this time.

About Dynasil Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures optical detection and analysis technology and components for the homeland security, medical and industrial markets.   Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing.  Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.

Forward-looking Statements

This news release may contain forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, our default under the financial covenants under our loan agreement with Santander Bank and Massachusetts Capital Resource Company, Xcede obtaining financing from outside investors, the commercialization of our products including our dual mode detectors, our development of new technologies including at Dynasil Biomedical, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures and the strength of our intellectual property portfolio.  These forward-looking statements may be identified by the use of words such as "plans", "intends," "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words.  The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to resolve our current default under our outstanding indebtedness,  our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, our ability to address our material weaknesses in our internal controls, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to deleverage our balance sheet, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's Annual Report on Form 10 K, filed on December 20, 2013, including the risk factors contained in Item 1a, the Company's Quarterly Report on Form 10-Q filed on February 12, 2014 and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Patty Kehe Corporate Secretary Dynasil Corporation of America Phone: (617) 668-6855 pkehe@dynasil.com

 

Dynasil Corporation of America and Subsidiaries

Consolidated Balance Sheet

ASSETS

December 31, 2013

September 30, 2013

Current Assets

   Cash and cash equivalents

$               2,755,356

$               2,436,828

   Accounts receivable, net

2,633,601

3,657,320

   Costs in excess of billings and unbilled receivables

2,292,809

1,537,318

   Inventories, net of reserves

2,678,524

3,140,244

   Prepaid expenses and other current assets

1,509,878

1,291,942

                     Total current assets

11,870,168

12,063,652

Property, Plant and Equipment, net

4,568,183

4,773,779

Other Assets

   Intangibles, net

1,357,492

3,484,583

   Goodwill

6,256,323

6,240,983

   Deferred financing costs, net

103,137

114,229

                     Total other assets

7,716,952

9,839,795

                     Total Assets

$             24,155,303

$             26,677,226

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

   Current portion of long-term debt

$               5,429,762

$               9,819,048

   Capital lease obligations, current

124,383

124,383

   Accounts payable

2,045,238

2,056,262

   Deferred revenue

347,688

515,790

   Accrued expenses and other liabilities

2,875,923

2,846,850

                     Total current liabilities

10,822,994

15,362,333

Long-term Liabilities

   Capital lease obligations, net of current portion

269,490

232,173

   Convertible notes

378,461

-

   Pension liability

249,966

249,966

   Deferred tax liability

183,417

186,866

                    Total long-term liabilities

1,081,334

669,005

Stockholders' Equity

   Dynasil stockholders' equity

12,263,162

10,645,888

Noncontrolling interest

(12,187)

-

                    Total stockholders' equity

12,250,975

10,645,888

Total Liabilities and Stockholders' Equity

$             24,155,303

$             26,677,226

 

Dynasil Corporation of America and Subsidiaries Consolidated Statement of Operations

Three Months Ended

December 31,

2013

2012

Net revenue

$        10,711,528

$        10,553,275

Cost of revenue

6,261,000

5,926,409

Gross profit

4,450,528

4,626,866

Operating expenses:

Sales and marketing expenses

396,805

479,878

Research and development expenses

346,197

637,129

General and administrative expenses

3,279,999

3,788,949

Total operating expenses

4,023,001

4,905,956

Gain on sale of assets

1,186,691

87,803

Income (loss) from operations

1,614,218

(191,287)

Interest expense, net

212,778

186,757

Income (loss) before taxes

1,401,440

(378,044)

Income tax (credit) provision

(44,043)

1,298

Net income (loss)

1,445,483

(379,342)

Less: Net loss attributable to noncontrolling interest

(12,187)

-

Net income (loss) attributable to common stockholders

$          1,457,670

$            (379,342)

Net income (loss)

$          1,445,483

$            (379,342)

Other comprehensive income (loss):

Foreign currency translation

36,164

29,739

Total comprehensive income (loss)

$          1,481,647

$            (349,603)

Basic net income (loss) per common share

$                  0.10

$                 (0.03)

Diluted net income (loss) per common share

$                  0.10

$                 (0.03)

Weighted average shares outstanding

Basic

15,021,757

14,673,356

Diluted

15,281,841

14,673,356

 

 

 

SOURCE Dynasil Corporation of America



RELATED LINKS

http://www.dynasil.com